1
|
DeRoin L, Cavalcante de Andrade Silva M, Petras K, Arndt K, Phillips N, Wanjari P, Subramanian HP, Montes D, McElherne J, Theissen M, Briese R, Das S, Godley LA, Segal J, Del Gaudio D, Fitzpatrick C, Churpek JE. Feasibility and limitations of cultured skin fibroblasts for germline genetic testing in hematologic disorders. Hum Mutat 2022; 43:950-962. [PMID: 35419889 PMCID: PMC9177640 DOI: 10.1002/humu.24374] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2021] [Revised: 03/05/2022] [Accepted: 03/26/2022] [Indexed: 12/19/2022]
Abstract
To avoid acquired variants found in the blood, cultured skin fibroblasts are a recommended DNA source for germline genetic testing in patients with hematologic disorders, but data are lacking regarding practicality and limitations. We conducted a retrospective cohort study of 350 subjects with hematologic disorders who underwent skin fibroblast culture for germline genetic testing. We analyzed next-generation sequencing data from the targeted capture of 144 inherited cancer and bonemarrow failure genes to identify variants at heterozygous and subclonal variant allele frequencies. Sixteen (5%) biopsies failed to culture. Culture failure was more likely in samples with delays in culture initiation (OR = 4.3; p < 0.01) or a pathogenic variant in a telomere gene (OR = 42.6; p < 0.01). Median culture time was 28 days (IQR 22-29 days). Culture time was longer for subjects with prior allogeneic stem cell transplantation (+10.7%; p = 0.02) and shorter in subjects with a heterozygous pathogenic variant (-11.9%; p < 0.01), larger biopsy size (-10.6%; p < 0.01), or lymphoid malignancy (-8.4%; p < 0.01). Subclonal variants were identified in 10 (4%) and confirmed in five (56%) of eight with alternate samples available. Subclonal and discordant variants illustrate that germline testing from cultured skin fibroblasts requires phenotypic correlation and, in rare cases, follow-up studies for optimal interpretation.
Collapse
Affiliation(s)
- Lia DeRoin
- Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA
| | | | - Kristin Petras
- Department of Pathology, University of Chicago, Chicago, Illinois, USA
| | - Kelly Arndt
- Department of Human Genetics, University of Chicago, Chicago, Illinois, USA
| | - Nathaniel Phillips
- Department of Human Genetics, University of Chicago, Chicago, Illinois, USA
| | - Pankhuri Wanjari
- Department of Pathology, University of Chicago, Chicago, Illinois, USA
| | | | - David Montes
- Department of Pathology, University of Chicago, Chicago, Illinois, USA
| | - James McElherne
- Department of Pathology, University of Chicago, Chicago, Illinois, USA
| | - Megan Theissen
- Department of Pathology, University of Chicago, Chicago, Illinois, USA
| | - Renee Briese
- Department of Pathology, University of Chicago, Chicago, Illinois, USA
| | - Soma Das
- Department of Human Genetics, University of Chicago, Chicago, Illinois, USA
| | - Lucy A Godley
- Section of Hematology/Oncology and Center for Clinical Cancer Genetics, University of Chicago, Chicago, Illinois, USA
| | - Jeremy Segal
- Department of Pathology, University of Chicago, Chicago, Illinois, USA
| | - Daniela Del Gaudio
- Department of Human Genetics, University of Chicago, Chicago, Illinois, USA
| | | | - Jane E Churpek
- Section of Hematology/Oncology and Center for Clinical Cancer Genetics, University of Chicago, Chicago, Illinois, USA
| |
Collapse
|
2
|
Cavalcante de Andrade Silva M, Katsumura KR, Mehta C, Velloso EDRP, Bresnick EH, Godley LA. Breaking the spatial constraint between neighboring zinc fingers: a new germline mutation in GATA2 deficiency syndrome. Leukemia 2020; 35:264-268. [PMID: 32286542 DOI: 10.1038/s41375-020-0820-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2020] [Revised: 03/18/2020] [Accepted: 03/27/2020] [Indexed: 12/31/2022]
Affiliation(s)
- Marcela Cavalcante de Andrade Silva
- Serviço de Hematologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, BR Av. Dr. Eneas de Carvalho 155, Cerqueira César, 01246-000, São Paulo, SP, Brazil.,Section of Hematology/Oncology and Center for Clinical Cancer Genetics, The University of Chicago, Chicago, IL, USA
| | - Koichi R Katsumura
- Department of Cell and Regenerative Biology, UW-Madison Blood Research Program, Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
| | - Charu Mehta
- Department of Cell and Regenerative Biology, UW-Madison Blood Research Program, Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
| | - Elvira D R P Velloso
- Serviço de Hematologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, BR Av. Dr. Eneas de Carvalho 155, Cerqueira César, 01246-000, São Paulo, SP, Brazil
| | - Emery H Bresnick
- Department of Cell and Regenerative Biology, UW-Madison Blood Research Program, Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
| | - Lucy A Godley
- Section of Hematology/Oncology and Center for Clinical Cancer Genetics, The University of Chicago, Chicago, IL, USA.
| |
Collapse
|
3
|
Trottier AM, Cavalcante de Andrade Silva M, Li Z, Godley LA. Somatic mutation panels: Time to clear their names. Cancer Genet 2019; 235-236:84-92. [PMID: 31101556 DOI: 10.1016/j.cancergen.2019.04.065] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2019] [Accepted: 04/23/2019] [Indexed: 10/26/2022]
Abstract
With improvements in DNA sequencing technologies and the consequent reduction in costs, next generation sequencing is being utilized increasingly in panel-based testing to perform molecular profiling of tumors. Such tumor-based panels are often referred to as 'somatic' panels, but this term is misleading and should not be used, since not all DNA variants within a tumor are somatic in nature. Every cell in a person's body contains that person's germline DNA, including tumor cells. Moreover, tumor samples are invariably contaminated with blood, a tissue that can contain somatic mutations itself in a process now called clonal hematopoiesis. Differentiating between germline variants or tumor-associated somatic mutations versus clonal hematopoiesis can be challenging. In this review, we address how to interpret the results of somatic mutation panels, how to differentiate between germline and truly somatic events, and discuss the importance of this distinction.
Collapse
Affiliation(s)
- Amy M Trottier
- Section of Hematology/Oncology, Department of Medicine, Comprehensive Cancer Center, The University of Chicago, 5841 S. Maryland Ave, MC 2115, Chicago, IL, 60637 United States
| | - Marcela Cavalcante de Andrade Silva
- Section of Hematology/Oncology, Department of Medicine, Comprehensive Cancer Center, The University of Chicago, 5841 S. Maryland Ave, MC 2115, Chicago, IL, 60637 United States; Hospital Universitario Prof Alberto Antunes -HU/UFAL, Maceio-AL, Brazil
| | - Zejuan Li
- Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, United States
| | - Lucy A Godley
- Section of Hematology/Oncology, Department of Medicine, Comprehensive Cancer Center, The University of Chicago, 5841 S. Maryland Ave, MC 2115, Chicago, IL, 60637 United States; Department of Human Genetics, The University of Chicago, Chicago, IL, United States.
| |
Collapse
|
4
|
Cavalcante de Andrade Silva M, Krepischi ACV, Kulikowski LD, Zanardo EA, Nardinelli L, Leal AM, Costa SS, Muto NH, Rocha V, Velloso EDRP. Deletion of RUNX1 exons 1 and 2 associated with familial platelet disorder with propensity to acute myeloid leukemia. Cancer Genet 2018; 222-223:32-37. [PMID: 29666006 DOI: 10.1016/j.cancergen.2018.01.002] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2017] [Accepted: 01/16/2018] [Indexed: 01/01/2023]
Abstract
Familial platelet disorder with propensity to acute myeloid leukemia (FPD/AML) associated with RUNX1 mutations is an autosomal dominant disorder included in the group of the myeloid neoplasms with germ line predisposition. We describe two brothers who were diagnosed with hematological malignancies (one with AML and the other with T-cell lymphoblastic lymphoma). There was a history of leukemia in the paternal family and two of their siblings presented with low platelet counts and no history of significant bleeding. A microdeletion encompassing exons 1-2 of RUNX1 (outside the cluster region of the Runt Homology domain and the transactivation domain) was detected in six family members using array-CGH and MLPA validation. A low platelet count was not present in all deletion carriers and, therefore, it should not be used as an indication for screening in suspected families and family members.
Collapse
Affiliation(s)
- Marcela Cavalcante de Andrade Silva
- Departamento de Hematologia, Laboratório de Citogenética, Hospital das Clinicas HCFMUSP, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR Av. Dr. Eneas de Carvalho 255, Cerqueira César 01246-000, São Paulo, SP, Brazil.
| | - Ana Cristina Victorino Krepischi
- Department of Genetics and Evolutionary Biology, Institute of Biosciences, University of São Paulo, SP, Brazil Rua do Matão, 321, Butantã, 05508-090, São Paulo, SP, Brazil.
| | - Leslie Domenici Kulikowski
- Departamento de Patologia, Laboratorio de Citogenomica do LIM 03, Hospital das Clinicas HCFMUSP, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR. Av. Dr. Eneas de Carvalho 255, Cerqueira César 01246-000, São Paulo, SP, Brazil.
| | - Evelin Aline Zanardo
- Departamento de Patologia, Laboratorio de Citogenomica do LIM 03, Hospital das Clinicas HCFMUSP, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR. Av. Dr. Eneas de Carvalho 255, Cerqueira César 01246-000, São Paulo, SP, Brazil
| | - Luciana Nardinelli
- Departamento de Hematologia, Laboratório Biologia Tumoral, Hospital das Clinicas HCFMUSP, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR Av. Dr. Eneas de Carvalho 255, Cerqueira César 01246-000, São Paulo, SP, Brazil
| | - Aline Medeiros Leal
- Departamento de Hematologia, Laboratório de Citogenética, Hospital das Clinicas HCFMUSP, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR Av. Dr. Eneas de Carvalho 255, Cerqueira César 01246-000, São Paulo, SP, Brazil
| | - Silvia Souza Costa
- Department of Genetics and Evolutionary Biology, Institute of Biosciences, University of São Paulo, SP, Brazil Rua do Matão, 321, Butantã, 05508-090, São Paulo, SP, Brazil
| | - Nair Hideki Muto
- Hospital Israelita Albert Einstein. Av. Albert Einstein, 627/701 Morumbi 05652- 900 - São Paulo, SP, Brazil.
| | - Vanderson Rocha
- Departamento de Hematologia, Laboratório de Citogenética, Hospital das Clinicas HCFMUSP, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR Av. Dr. Eneas de Carvalho 255, Cerqueira César 01246-000, São Paulo, SP, Brazil; Departamento de Hematologia, Laboratório Biologia Tumoral, Hospital das Clinicas HCFMUSP, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR Av. Dr. Eneas de Carvalho 255, Cerqueira César 01246-000, São Paulo, SP, Brazil
| | - Elvira Deolinda Rodrigues Pereira Velloso
- Departamento de Hematologia, Laboratório de Citogenética, Hospital das Clinicas HCFMUSP, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR Av. Dr. Eneas de Carvalho 255, Cerqueira César 01246-000, São Paulo, SP, Brazil; Hospital Israelita Albert Einstein. Av. Albert Einstein, 627/701 Morumbi 05652- 900 - São Paulo, SP, Brazil.
| |
Collapse
|
5
|
Belli CB, Pinheiro RF, Bestach Y, Larripa IB, da Silva Tanizawa RS, Alfonso G, Gonzalez J, Rosenhain M, Watman N, Cavalcante de Andrade Silva M, Negri Aranguren P, García Rivello H, Magalhaes SM, Valladares X, Undurraga MS, Velloso ER. Myelodysplastic syndromes in South America: a multinational study of 1080 patients. Am J Hematol 2015; 90:851-8. [PMID: 26104573 DOI: 10.1002/ajh.24097] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2015] [Revised: 06/18/2015] [Accepted: 06/19/2015] [Indexed: 01/23/2023]
Abstract
There are previously reported data describing differences between Asian and European patients with Myelodysplastic Syndromes (MDS), few direct comparisons based on cancer registration characteristics or using cohorts to validate scoring systems. This is the first study from South-America, which attempts to describe demographic, clinical features, and outcome of MDS patients. We retrospectively analyzed 1,080 patients with de novo MDS from Argentina (635), Brazil (345), and Chile (100). Chilean patients were younger (P = 0.001) with female preponderance (P = 0.071). Brazilian series showed a higher predominance of RARS subtype regarding FAB and WHO classifications (P < 0.001). Hemoglobin levels were significantly lower in Brazilian and Chilean series (P < 0.001), and Chilean series also showed a lower platelet count (P = 0.028), with no differences concerning the neutrophil count, % BM blast, and the distribution of cytogenetic risk groups (P > 0.05). Chilean series depicted a lower overall survival (OS; 35 months vs. 56 months-Argentine; 55 months-Brazil, P = 0.030), which was consistent with a higher predominance of the high-risk group according both to the IPSS and IPSS-R (P = 0.046 and P < 0.001). The IPSS-R system and its variables showed a good reproducibility to predict clinical outcome for the whole South-American population. Epidemiological and clinical characteristics, distribution among prognostic subgroups, the OS, and the access to disease modifying therapies were more similar between Argentinean and Brazilian compared with Chilean MDS series. This will need further analysis in a larger group of patients. Descriptive and comparative studies are necessary to establish epidemiological features useful for public health attitudes to generate suitable therapeutic schemes.
Collapse
Affiliation(s)
- Carolina B. Belli
- Instituto de Medicina Experimental (IMEX-CONICET)/Academia Nacional de Medicina; Laboratorio de Genética Hematológica; Buenos Aires Argentina
- On behalf of the Grupo de Estudio de SMD, Sociedad Argentina de Hematología; Buenos Aires Argentina
| | | | - Yesica Bestach
- Instituto de Medicina Experimental (IMEX-CONICET)/Academia Nacional de Medicina; Laboratorio de Genética Hematológica; Buenos Aires Argentina
| | - Irene B. Larripa
- Instituto de Medicina Experimental (IMEX-CONICET)/Academia Nacional de Medicina; Laboratorio de Genética Hematológica; Buenos Aires Argentina
| | | | - Graciela Alfonso
- Servicio de Hematología; Hospital General de Agudos “A. J. Posadas”; El Palomar Argentina
- On behalf of the Grupo de Estudio de SMD, Sociedad Argentina de Hematología; Buenos Aires Argentina
| | - Jacqueline Gonzalez
- Servicio de Hematología, Hospital General de Agudos “C Durand,”; Buenos Aires Argentina
- On behalf of the Grupo de Estudio de SMD, Sociedad Argentina de Hematología; Buenos Aires Argentina
| | - Mariana Rosenhain
- Servicio de Hematología; Hospital General de Agudos “Tornú,”; Buenos Aires Argentina
- On behalf of the Grupo de Estudio de SMD, Sociedad Argentina de Hematología; Buenos Aires Argentina
| | - Nora Watman
- Servicio de Hematología; Hospital General de Agudos “Ramos Mejía,”; Buenos Aires Argentina
| | | | | | - Hernán García Rivello
- Servicio de Patología; Hospital Italiano de, Buenos Aires; Argentina
- On behalf of the Grupo de Estudio de SMD, Sociedad Argentina de Hematología; Buenos Aires Argentina
| | | | | | | | - Elvira R.P. Velloso
- Hematology and Transfusion Medicine; Hospital Das Clinicas, University of Sao Paulo; Brazil
| |
Collapse
|
6
|
Dias AR, de Andrade Silva MC, Carvalho FM, de Andrade Carvalho H, Esteves Diz MDP, Baracat EC, Carvalho JP. Fanconi anemia and vaginal squamous cell carcinoma. Rare Tumors 2012; 4:e4. [PMID: 22532920 PMCID: PMC3325749 DOI: 10.4081/rt.2012.e4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2011] [Revised: 11/16/2011] [Accepted: 11/17/2011] [Indexed: 11/23/2022] Open
Abstract
Fanconi Anemia (FA) is an autosomal recessive disease characterized by chromosome instability, cellular hypersensitivity to DNA cross-linking agents, and increased predisposition to malignancies. We describe here a 28 year-old female with FA and vaginal squamous cell carcinoma treated by radiation therapy alone. The patient developed arm phlebitis, pulmonary fungal infection, and severe rectal bleeding, followed by hypocalcaemia, hypokalemia, vaginal bacterial and fungal infection, with subsequent leg and arm phlebitis, perineal abscess, and sepsis. The patient died 12 weeks later.
Collapse
|